Dexamethasone's Connection to COVID-19

Authors

  • Bianca Mammarella McMaster
  • Sarah Damiani York University

DOI:

https://doi.org/10.15173/sciential.v1i9.3198

Keywords:

COVID-19, Dexamethasone, Corticosteroid, Glucocorticoid, Recovery Trial

Abstract

Dexamethasone is known for its use as an anti-inflammatory and immunosuppressant medication. This medication has been present for many years, and its benefits have been observed in the treatment of various conditions. With the rise of COVID-19 cases on an international scale, healthcare professionals globally searched for a therapeutic medication, either existing or under development that could help those who were ill with the virus. The Recovery Trial aims to find a pharmacotherapeutic medication that would assist in treating hospitalized individuals who were diagnosed with COVID-19. In this trial, Dexamethasone’s ability to reduce hospitalization durations, and patient fatality was observed. These results increased curiosity about Dexamethasone's potential in the fight against COVID-19. As we work towards a standardized treatment plan for COVID-19, investigate Dexame- thasone’s mechanisms of action, and how it impacts different populations; together, these findings may help to determine this medication’s effectiveness as a COVID-19 treatment option.

Downloads

Published

2022-12-17

How to Cite

Mammarella, B., & Damiani, S. (2022). Dexamethasone’s Connection to COVID-19. Sciential - McMaster Undergraduate Science Journal, 1(9), 55–59. https://doi.org/10.15173/sciential.v1i9.3198

Issue

Section

News and Views